Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deramciclane (Egis).

Sulev Kõks1, Eero Vasar

  • 1Department of Physiology, University of Tartu, Estonia. Sulev.Koks@ut.ee

Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>GCH1</i> p.Ser80Asn Confers Risk for Parkinson's Disease in East Asian Populations.

medRxiv : the preprint server for health sciences·2026
Same author

Comparison of Proteomic Analysis of Cerebrospinal Fluid From Neurological Patients With and Without Amyotrophic Lateral Sclerosis.

Journal of neurochemistry·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Longitudinal Repeatome Remodeling in Peripheral Blood Following Parkinson's Disease Diagnosis.

Genes·2026
Same author

Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.

NPJ Parkinson's disease·2026
Same author

Genome-wide association study of copy number variations in Parkinson's disease.

NPJ Parkinson's disease·2026

Deramciclane, a novel 5-HT(2A) antagonist and 5-HT(2C) inverse agonist, is progressing through Phase III trials for anxiety disorders. Global commercialization plans are underway, with anticipated NDA filing in 2004.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Drug Development

Background:

  • Deramciclane is a selective serotonin receptor antagonist and inverse agonist.
  • It is being developed for anxiety disorders.
  • Previous development for epilepsy has been discontinued.

Purpose of the Study:

  • To evaluate the efficacy and safety of deramciclane in treating anxiety disorders.
  • To advance deramciclane towards regulatory submission and commercialization.

Main Methods:

  • Phase III clinical trials conducted across multiple European countries and South Africa.
  • Collaborative development and commercialization agreements between Egis, Orion Pharma, and Pharmacia.

Main Results:

Related Experiment Videos

  • Phase III studies are progressing as planned.
  • Regulatory filings (NDA) are anticipated by 2004.
  • Commercialization efforts are underway globally, including a US collaboration.

    • Conclusions:

    • Deramciclane shows promise as a treatment for anxiety disorders.
    • The drug is on track for potential market entry around 2004.
    • Significant market potential is projected by financial analysts.